Beyond PD-L1: Challenges in Implementing Tumor Mutational Burden (TMB) to Predict Patient Response to Immuno-Oncology (IO) Therapies

被引：0
作者：
Krein, P. M. [1 ]
机构：
[1] Diaceutics Inc, Parsippany, NJ USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2017年 / 19卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST129
引用
收藏
页码：1039 / 1039
页数：1
相关论文
共 50 条
  • [31] A retrospective analysis to evaluate prevalence and correlation between PD-L1 score and tumor mutational burden (TMB) levels in patients with solid tumor malignancies
    Kazmi, S. M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Association of tumor mutational burden (TMB) with DNA repair mutations and response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer (NSCLC)
    Davis, Andrew A.
    Chae, Young Kwang
    Agte, Sarita
    Pan, Alan
    Mohindra, Nisha
    Villaflor, Victoria
    Raparia, Kirtee
    Giles, Francis J.
    CANCER RESEARCH, 2017, 77
  • [33] PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
    Yarchoan, Mark
    Albacker, Lee A.
    Hopkins, Alexander C.
    Montesion, Meagan
    Murugesan, Karthikeyan
    Vithayathil, Teena T.
    Zaidi, Neeha
    Azad, Nilofer S.
    Laheru, Daniel A.
    Frampton, Garrett M.
    Jaffee, Elizabeth M.
    JCI INSIGHT, 2019, 4 (06)
  • [34] PD-L1, Tumor Mutational Burden (TMB) and Intracranial Outcomes in Patients with Non -Small Cell Lung Cancer (NSCLC) and Brain Metastases
    Adib, E.
    Nassar, A. H.
    Kwiatkowski, D. J.
    Aizer, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E213 - E213
  • [35] Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough
    Weinberg, Benjamin A.
    Xiu, Joanne
    Hwang, Jimmy J.
    Shields, Anthony F.
    Salem, Mohamed E.
    Marshall, John L.
    ONCOLOGIST, 2018, 23 (10) : 1171 - 1177
  • [36] In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh, Sandrine
    Matias, Margarida
    Palomar, Virginia
    Dercle, Laurent
    Lanoy, Emilie
    Soria, Jean-Charles
    Postel-Vinay, Sophie
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 65 - 74
  • [37] Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesophageal cancers.
    Cerniglia, Michael
    Xiu, Joanne
    Grothey, Axel
    Pishvaian, Michael J.
    Hwang, Jimmy J.
    Marshall, John
    Vanderwalde, Ari M.
    Shields, Anthony Frank
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    Philip, Philip Agop
    Goldberg, Richard M.
    Korn, W. Michael
    Kim, Sunnie S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [38] PD-L1, Tumor Mutational Burden, and Outcomes in NSCLC With Brain Metastases: A Brief Report
    Adib, Elio
    Nassar, Amin H.
    Farhat, Elias Bou
    Tanguturi, Shyam K.
    Rahman, Rifaquat M.
    Haas-Kogan, Daphne A.
    Bi, Wenya Linda
    Arnaout, Omar
    Wen, Patrick Y.
    Kwiatkowski, David J.
    Awad, Mark M.
    Aizer, Ayal A.
    JTO CLINICAL AND RESEARCH REPORTS, 2025, 6 (04):
  • [39] Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC
    Ippolito, Alberto
    Wang, Hanwen
    Zhang, Yu
    Vakil, Vahideh
    Popel, Aleksander S.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (06) : 747 - 757
  • [40] Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.
    George, Thomas J.
    Frampton, Garrett Michael
    Sun, James
    Gowen, Kyle
    Kennedy, Mark
    Greenbowe, Joel R.
    Schrock, Alexa Betzig
    Ali, Siraj Mahamed
    Klempner, Samuel Jacob
    Flezel, Aram F.
    Ross, Jeffrey S.
    Stephens, Phil
    Miller, Vincent A.
    Fabrizio, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345